Phase 2 Stroke Trial, Recruiting NCT07397923 Sponsor: Seoul National University Bundang Hospital Condition: Stroke
Back to Stroke

Phase 2 Stroke Trial, Recruiting

NCT07397923
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 19 years or older
  • People whose aphasia (difficulty with speaking or understanding language) has been confirmed by a specialist to be caused by a stroke
  • People who have had their first-ever stroke within the last 3 months, confirmed by a brain scan such as a CT or MRI
  • People who have been diagnosed with aphasia using a specific speech assessment tool called the PK-WAB-R
  • People whose first (native) language is Korean

Who may not be able to join:

  • People whose stroke is still progressing or is medically unstable
  • People who have other brain or nervous system conditions that may also affect their ability to use language
  • People who have a major mental health condition — such as severe depression, schizophrenia, bipolar disorder, or dementia — that requires ongoing medication
  • People who have a major neurological (brain or nervous system) disease in addition to their stroke
  • People with a confirmed history of a degenerative nerve condition
  • People with a current or past history of substance or alcohol use disorder
  • People with significant vision impairment, specifically a visual acuity measurement between 0.1 and 0.3 or lower (confirm with trial site)
  • People with an intellectual disability
  • People who are unable to read or to provide informed consent

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +82-31-787-7737

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Seoul National University Bundang Hospital
Registry
ClinicalTrials.gov
Start date
10 December 2025
Est. completion
30 June 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

PK-WAB AQ(Korean Version of PK-WAB-R AQ)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov